Comparative Pharmacology
Head-to-head clinical analysis: MD 60 versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 60 versus MD 76R.
MD-60 vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-60 is a nonionic iodinated contrast agent. It attenuates X-rays by increasing the density of structures and organs, improving radiographic visualization.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Intravenous administration, 60 mg/kg as a single dose over 30 min.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function (CrCl >90 mL/min); prolonged to >40 hours in moderate renal impairment (CrCl 30–60 mL/min), requiring dose adjustment.
Terminal half-life 1-2 hours; prolonged in renal impairment.
Primarily renal elimination of unchanged drug (~60% within 24 hours) via glomerular filtration; biliary/fecal excretion accounts for ~30% as metabolites; ~10% undergoes enterohepatic recirculation.
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent